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Isocitrate dehydrogenase (IDH) mutations are the first
mutations that occur during the oncogenic process of
lower-grade glioma (LGG) and confers a novel gain-of-
function activity by converting a-ketoglutarate (aKG) to
2-hydroxyglutarate (2HG), promoting DNA hyper-
methylation. Our analysis of LGG cases from The Can-
cer Genome Atlas (TCGA) database revealed that IDH-
mutant (IDH-Mut) cases exhibit decreased expression of
type-1 effector T cell response-related genes, which are
critical for anti-glioma immunity, including: CD8A,
IFNG, OAS2, GZMA, EOMES, CXCL9 and CXCL10,
compared with IDH-wild type (IDH-WT) cases. On the
other hand, type-2 and regulatory T cell response-
related genes, such as IL5 and TGFB1, are not signifi-
cantly different between IDH-Mut vs. WT cases, indicat-
ing that the observed down-regulation of type-1
response-related genes does not merely represent a pos-
sible global gene suppression. Furthermore, IDH-Mut
cases exhibit increased CXCL10 promotor methylation
compared with WT cases. We thus hypothesized that
IDH mutation-mediated tumor intrinsic mechanisms
occurring within glioma cells may inhibit anti-tumor
immunity to promote tumor growth. In vitro, a normal
human astrocyte (NHA) cell line transfected with IDH1-
Mut cDNA expressed lower levels of CXCL10 compared
to NHA cells transfected with WT IDH1. Consistently,
C57Bl/6 mouse-syngeneic astrocyte and glioma cell lines
transfected with IDH1-Mut expressed lower levels of
CXCL10 gene and protein, compared to control cells
transfected with IDH-WT, which was restored following
30 day treatment of the cells with the IDH1 inhibitor,
IDH-C35. Furthermore, in vivo orthotopic IDH1-Mut
gliomas at 21 days post-intracranial injection in syn-
geneic mice expressed lower levels of T cell chemokines
CXCL9 and CXCL10 as determined by RT-PCR and
ELISA and reduced infiltration of CD3+CD8+ T cells as
determined by flow cytometry and quantitative immuno-
histochemistry compared with control IDH1-WT gliomas.
Further, an in vitro migration assay demonstrated reduced
migration of T cells towards culture supernatants from
IDH1-Mut cell lines compared with control supernatants
derived from IDH1-WT cells. Overall, our data demon-
strate that IDH mutations in tumor cells lead to reduced
T cell attracting chemokines and reduced T cell accumula-
tion in gliomas. Our analyses of the TCGA 450K gene
methylation database suggest that the suppressed expres-
sion of OAS2 and CXCL10 in IDH1-Mut cases is asso-
ciated with hypermethylation of the promoter for these
genes. Indeed, treatment of IDH-Mut cell lines with
demethylating agent 5-Aza-CdR restored CXCL10 expres-
sion levels. Our data suggest that IDH inhibitors and
demethylation agents may be used to enhance T cell
recruitment to LGG in combination with T cell based
immunotherapies.
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